• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Prospective analysis of HLA classes I and II antigen frequency in patients with Peyronie's disease.

作者信息

Hauck Ekkehard W, Hauptmann Arne, Weidner Wolfgang, Bein Gregor, Hackstein Holger

机构信息

Department of Urology, Justus Liebig University, Giessen, Germany.

出版信息

J Urol. 2003 Oct;170(4 Pt 1):1443-6. doi: 10.1097/01.ju.0000076488.89748.e1.

DOI:10.1097/01.ju.0000076488.89748.e1
PMID:14501786
Abstract

PURPOSE

The pathogenesis of Peyronie's disease remains unclear. Previous studies have described possible associations among various HLAs and Peyronie's disease. However, only small series comprising 9 to 52 patients were analyzed in these studies and published results are controversial. We prospectively investigated a possible association of Peyronie's disease with HLA classes I and II specificity in a large patient group.

MATERIALS AND METHODS

A total of 154 consecutive patients with Peyronie's disease were typed serologically for HLA class I antigens. Molecular typing of HLA class II alleles was performed by polymerase chain reaction sequence specific primers. Results were compared with those in healthy bone marrow donors for HLA classes I (2,450) and II (316), serving as representative controls selected from the local population. In addition, HLA distribution in a German normal cohort of 14,835 individuals served as a control.

RESULTS

No significant difference in HLA classes I and II antigen frequency was evident in patients with Peyronie's disease compared with healthy controls.

CONCLUSIONS

The results of this study do not indicate any significant association between Peyronie's disease and antigens of the HLA system.

摘要

相似文献

1
Prospective analysis of HLA classes I and II antigen frequency in patients with Peyronie's disease.
J Urol. 2003 Oct;170(4 Pt 1):1443-6. doi: 10.1097/01.ju.0000076488.89748.e1.
2
Peyronie's disease is associated with an HLA class II antigen, HLA-DQ5, implying an autoimmune etiology.
J Urol. 1996 Oct;156(4):1330-4.
3
Is there an immunogenetic basis for Peyronie's disease?
J Urol. 1997 Jan;157(1):295-7.
4
HLA antigens in Peyronie's disease.佩罗尼氏病中的人类白细胞抗原
Urol Int. 1994;52(1):34-7. doi: 10.1159/000282566.
5
HLA association of idiopathic Peyronie's disease: an indication of autoimmune phenomena in etiopathogenesis?特发性佩罗尼氏病与人类白细胞抗原的关联:病因发病机制中自身免疫现象的一个指征?
Tissue Antigens. 1991 Sep;38(3):104-6. doi: 10.1111/j.1399-0039.1991.tb02021.x.
6
The genetic and bacteriological aspects of Peyronie's disease.佩罗尼氏病的遗传学和细菌学方面
J Urol. 1997 Jan;157(1):291-4.
7
The genetics and immunology of Peyronie's disease.佩罗尼氏病的遗传学与免疫学
Int J Impot Res. 2000 Oct;12 Suppl 4:S127-32. doi: 10.1038/sj.ijir.3900591.
8
Alpha-1-antitrypsin levels and genetic variation of the alpha-1-antitrypsin gene in Peyronie's disease.佩罗尼氏病中α-1抗胰蛋白酶水平及α-1抗胰蛋白酶基因的遗传变异
Eur Urol. 2004 Nov;46(5):623-8; discussion 628. doi: 10.1016/j.eururo.2004.04.028.
9
Prospective analysis of single nucleotide polymorphisms of the transforming growth factor beta-1 gene in Peyronie's disease.佩罗尼氏病中转化生长因子β-1基因单核苷酸多态性的前瞻性分析。
J Urol. 2003 Jan;169(1):369-72. doi: 10.1016/S0022-5347(05)64129-8.
10
Non-association of Peyronie's disease with HLA B7 cross-reactive antigens.佩罗尼氏病与HLA B7交叉反应抗原无关联。
J Urol. 1982 Jun;127(6):1223-4. doi: 10.1016/s0022-5347(17)54302-5.

引用本文的文献

1
Significant familial clustering of Peyronie's disease in close and distant relatives.在近亲及远亲中,存在显著的 Peyronie 病家族聚集性。
Andrology. 2022 Oct;10(7):1361-1367. doi: 10.1111/andr.13223. Epub 2022 Jul 13.
2
ABO Blood Type and Risk of Peyronie's Disease in Japanese Males.日本男性的ABO血型与佩罗尼氏病风险
World J Mens Health. 2022 Jul;40(3):509-516. doi: 10.5534/wjmh.210126. Epub 2022 Jan 1.
3
Molecular Mechanisms and Current Pharmacotherapy of Peyronie's Disease: A Review.佩罗尼氏病的分子机制与当前药物治疗:综述
Front Pharmacol. 2021 May 20;12:643641. doi: 10.3389/fphar.2021.643641. eCollection 2021.
4
Peyronie's disease: is it genetic or not?佩罗尼氏病:它有遗传性吗?
Transl Androl Urol. 2020 Mar;9(Suppl 2):S262-S268. doi: 10.21037/tau.2019.10.21.
5
The Genetic Basis of Peyronie Disease: A Review.《佩罗尼病的遗传学基础:综述》。
Sex Med Rev. 2016 Jan;4(1):85-94. doi: 10.1016/j.sxmr.2015.10.002. Epub 2016 Jan 8.
6
PEYRONIE'S DISEASE: A REVIEW OF ETIOLOGY, DIAGNOSIS, AND MANAGEMENT.佩罗尼氏病:病因、诊断与治疗综述
Curr Sex Health Rep. 2015 Jun 1;7(2):117-131. doi: 10.1007/s11930-015-0045-y.
7
Intralesional hyaluronic acid: an innovative treatment for Peyronie's disease.病灶内注射透明质酸:佩罗尼氏病的创新疗法。
Int Urol Nephrol. 2015 Oct;47(10):1595-602. doi: 10.1007/s11255-015-1074-1. Epub 2015 Aug 11.
8
Tunica albuginea allograft: a new model of LaPeyronie's disease with penile curvature and subtunical ossification.白膜同种异体移植:一种伴有阴茎弯曲和白膜下骨化的佩罗尼氏病新模型。
Asian J Androl. 2014 Jul-Aug;16(4):592-6. doi: 10.4103/1008-682X.125900.
9
Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy.采用 PDE5 抑制剂治疗 Peyronie 病:一种抗纤维化策略。
Nat Rev Urol. 2010 Apr;7(4):215-21. doi: 10.1038/nrurol.2010.24. Epub 2010 Mar 9.
10
[Retroperitoneal fibrosis].[腹膜后纤维化]
Urologe A. 2008 Apr;47(4):489-499. doi: 10.1007/s00120-008-1705-6.